Stock Screener App

Free -

Install

0.00

100.00% -0.2075

Casi Pharmaceuticals Inc (CASI)

Overview News Price History Option Chain Financials Discussions Forecast Stock Split

Casi Pharmaceuticals Inc stock is traded at $0.00, with a volume of 0. It is down -100.00% in the last 24 hours and down -100.00% over the past month. CASI Pharmaceuticals Inc is a biopharmaceutical company that focuses on commercializing therapeutics and pharmaceutical products. The products include injections for patients who are suffering from leukemias and lymphomas. The EVOMELA injection is used as a conditioning treatment before autologous stem cell transplant for patients with multiple myeloma. The company products include CID-103, CNCT19, EVOMELA, MARQIBO, ZEVALIN, ENMD-2076 and others. The majority of the revenue is generated from the product sales of EVOMELA.

See More

Previous Close:

$0.2075

Open:

$0

24h Volume:

0

Relative Volume:

0.00

Market Cap:

$4.26M

Revenue:

$31.56M

Net Income/Loss:

$-46.89M

P/E Ratio:

0.00

EPS:

-3.0329

Net Cash Flow:

$-26.70M

1W Performance:

-100.00%

1M Performance:

-100.00%

6M Performance:

-100.00%

1Y Performance:

-100.00%

1-Day Range:

$0.00

$0.00

1-Week Range:

$0.00

$0.00

52-Week Range:

$0.00

$3.09

Casi Pharmaceuticals Inc Stock (CASI) Company Profile

Name

Casi Pharmaceuticals Inc

Sector

Healthcare (1109)

Industry

Biotechnology (616)

Phone

-

Address

-

Employee

233

Twitter

Next Earnings Date

2024-11-14

Latest SEC Filings

CASI's Discussions on Twitter

Compare CASI vs VRTX, REGN, ARGX, ALNY, ONC

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
CASI Casi Pharmaceuticals Inc	0.00	4.26M	31.56M	-46.89M	-26.70M	-3.0329
VRTX Vertex Pharmaceuticals Inc	492.38	125.08B	12.07B	3.95B	3.19B	15.33
REGN Regeneron Pharmaceuticals Inc	774.66	81.90B	14.34B	4.50B	3.77B	41.56
ARGX Argen X Se Adr	728.09	45.06B	4.16B	1.29B	734.26M	19.59
ALNY Alnylam Pharmaceuticals Inc	320.43	42.50B	3.71B	313.75M	465.38M	2.2571
ONC Beone Medicines Ltd Adr	298.91	33.16B	5.36B	287.73M	924.18M	2.5229

Casi Pharmaceuticals Inc Stock (CASI) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
May-18-21	Initiated	BTIG Research	Buy
Apr-26-21	Initiated	Mizuho	Buy
Oct-23-20	Initiated	Oppenheimer	Outperform
Sep-22-16	Initiated	Maxim Group	Buy
Oct-29-15	Resumed	H.C. Wainwright	Buy
Jun-23-15	Initiated	H.C. Wainwright	Buy

View All

Casi Pharmaceuticals Inc Stock (CASI) Latest News

Short Squeeze: Can CASI Pharmaceuticals Inc deliver consistent EPS growth2025 Valuation Update & Daily Stock Momentum Reports - baoquankhu1.vn

CASI Pharmaceuticals Inc. (CASIF) Price To Cash Flow - Zacks Investment Research

CASI Pharmaceuticals Inc. (CASIF) Total Liabilities - Zacks Investment Research

CASI Pharmaceuticals Inc. (CASIF) Return On Equity (TTM) - Zacks Investment Research

CASI Pharmaceuticals Inc. (CASIF) Total Long Term Debt (Quarterly) - Zacks Investment Research

CASI Pharmaceuticals Inc. (CASIF) Enterprise Value - Zacks Investment Research

CASI Pharmaceuticals Inc. (CASIF) Total Expenses (Quarterly) - Zacks Investment Research

CASI Pharmaceuticals Inc. (CASIF) Book Value - Zacks Investment Research

CASI PHARMACEUTICALS INC (CASIF.US) Income Statements, Balance Sheet & Cashflow - Longbridge

CASI PHARMACEUTICALS INC (CASIF.US) Latest News & Headlines - Longbridge

CASI Pharmaceuticals, Inc.: Financial Data Forecasts Estimates and Expectations | CASIF | KYG1933S1012 - marketscreener.com

CASI Pharmaceuticals, Inc.: Target Price Consensus and Analysts Recommendations | CASIF | KYG1933S1012 - marketscreener.com

CASI Pharmaceuticals, Inc.: Revenue and Earnings Analysts Forecasts Revisions | CASIF | KYG1933S1012 - marketscreener.com

Casi Pharmaceuticals CEO David Cory to step down at end of March - Investing.com

CASI Pharmaceuticals CEO David Cory to Step Down; Executive Chairman Wei-Wu He Assumes Top Role - TipRanks

Leadership change at CASI Pharmaceuticals (NASDAQ: CASI) as CEO exits - Stock Titan

CASI Pharmaceuticals Inc. (CASIF) Gross Margin (TTM) - Zacks Investment Research

CASI Pharmaceuticals Inc. (CASIF) Debt Equity Ratio (Quarterly) - Zacks Investment Research

CASI Pharmaceuticals Inc. (CASIF) - Zacks Investment Research

CASI Pharmaceuticals Inc. (CASIF) Price Book Value - Zacks Investment Research

CASI Pharmaceuticals Inc. (CASIF) Cash From Operations (TTM) - Zacks Investment Research

CASIF (CASI Pharmaceuticals) PB Ratio : (As of Mar. 02, 2026) - GuruFocus

CASI Pharmaceuticals Inc. (CASIF) Return On Assets (TTM) - Zacks Investment Research

Net debt of CASI Pharmaceuticals, Inc. – OTC:CASIF - TradingView

CASI Pharmaceuticals Inc. (CASIF) Earnings Yield (TTM) - Zacks Investment Research

EBIT per share of CASI Pharmaceuticals, Inc. – OTC:CASIF - TradingView

EBITDA margin % of CASI Pharmaceuticals, Inc. – OTC:CASIF - TradingView

After tax other income/expense of CASI Pharmaceuticals, Inc. – OTC:CASIF - TradingView

Long term debt to total equity ratio of CASI Pharmaceuticals, Inc. – OTC:CASIF - TradingView

Operating expenses (excl. COGS) of CASI Pharmaceuticals, Inc. – OTC:CASIF - TradingView

CapEx per share of CASI Pharmaceuticals, Inc. – OTC:CASIF - TradingView

Net current asset value per share of CASI Pharmaceuticals, Inc. – OTC:CASIF - TradingView

Preferred dividends of CASI Pharmaceuticals, Inc. – OTC:CASIF - TradingView

Enterprise value to EBITDA ratio of CASI Pharmaceuticals, Inc. – OTC:CASIF - TradingView

Working capital per share of CASI Pharmaceuticals, Inc. – OTC:CASIF - TradingView

Total debt of CASI Pharmaceuticals, Inc. – OTC:CASIF - TradingView

Free cash flow per share of CASI Pharmaceuticals, Inc. – OTC:CASIF - TradingView

Total debt per share of CASI Pharmaceuticals, Inc. – OTC:CASIF - TradingView

CASI Pharmaceuticals, Inc. Balance Sheet – OTC:CASIF - TradingView

Technical Analysis of CASI Pharmaceuticals, Inc. (OTC:CASIF) - TradingView

CASI Pharmaceuticals Inc. (CASIF) Revenue (Quarterly) Yoy Growth - Zacks Investment Research

CASI Pharmaceuticals Inc. (CASIF) Total Expenses (TTM) - Zacks Investment Research

Diluted shares outstanding of CASI Pharmaceuticals, Inc. – OTC:CASIF - TradingView

Gross profit of CASI Pharmaceuticals, Inc. – OTC:CASIF - TradingView

EBIT of CASI Pharmaceuticals, Inc. – OTC:CASIF - TradingView

Dilution adjustment of CASI Pharmaceuticals, Inc. – OTC:CASIF - TradingView

Non-controlling/minority interest of CASI Pharmaceuticals, Inc. – OTC:CASIF - TradingView

Free cash flow of CASI Pharmaceuticals, Inc. – OTC:CASIF - TradingView

CASI Pharmaceuticals, Inc. Statistics – OTC:CASIF - TradingView

EBITDA of CASI Pharmaceuticals, Inc. – OTC:CASIF - TradingView

Pretax income of CASI Pharmaceuticals, Inc. – OTC:CASIF - TradingView

Casi Pharmaceuticals Inc Stock (CASI) Financials Data

Revenue

Net Income

Cash Flow

EPS

RPRX

$46.69

1.57%

ROIV

$29.58

0.40%

MRNA

$55.97

1.80%

BNTX

$90.84

8.28%

INSM

$139.40

3.09%

ONC

$298.91

2.12%

Open in Yahoo | Open in Google | Open in Finviz | Open in MarketWatch | Open in EDGAR | Open in Reuters